Imperial College London

ProfessorPatrickSerruys

Faculty of MedicineNational Heart & Lung Institute

Visiting Professor
 
 
 
//

Contact

 

p.serruys

 
 
//

Location

 

c/o Prof Kim FoxGuy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Onuma:2008:10.4244/eijv3i5a99,
author = {Onuma, Y and Müller, R and Ramcharitar, S and van, Geuns R-JM and Louvard, Y and Morel, M-A and Morice, M-C and Davis, R and Kaplan, AV and Lefèvre, T and Grube, E and Serruys, PW},
doi = {10.4244/eijv3i5a99},
journal = {EuroIntervention},
pages = {546--552},
title = {Tryton I, First-In-Man (FIM) study: six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions.},
url = {http://dx.doi.org/10.4244/eijv3i5a99},
volume = {3},
year = {2008}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - AIM: To report clinical and angiographic follow-up at 6 months after implantation of the Tryton Side-Branch Stent dedicated to bifurcation, in conjunction with standard workhorse drug-eluting stent (DES). METHODS AND RESULTS: Patients having angina or silent myocardial ischaemia with de novo bifurcation lesions were enrolled at three sites. The Tryton stent was first placed in the side-branch and a standard DES subsequently implanted in the main-branch. The primary endpoint was freedom from in-hospital major adverse cardiac events (MACE) following procedural success. Angiographic and clinical follow-up was performed at 6-months. Quantitative coronary angiography (QCA) was analysed with a new dedicated bifurcation software. Thirty patients were enrolled. At six months clinical follow-up was available in 100% with angiographic follow-up performed in 78%. The primary endpoint was met in 93.3%. The MACE rate at 6 months was 9.9%. QCA analysis demonstrated late luminal loss of 0.17 mm with no restenosis in the side branch. CONCLUSIONS: In conjunction with a workhorse DES to treat bifurcation lesions, the Tryton side-branch stent demonstrated acceptable clinical outcome and low side-branch late loss at six months.
AU - Onuma,Y
AU - Müller,R
AU - Ramcharitar,S
AU - van,Geuns R-JM
AU - Louvard,Y
AU - Morel,M-A
AU - Morice,M-C
AU - Davis,R
AU - Kaplan,AV
AU - Lefèvre,T
AU - Grube,E
AU - Serruys,PW
DO - 10.4244/eijv3i5a99
EP - 552
PY - 2008///
SN - 1774-024X
SP - 546
TI - Tryton I, First-In-Man (FIM) study: six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions.
T2 - EuroIntervention
UR - http://dx.doi.org/10.4244/eijv3i5a99
UR - https://www.ncbi.nlm.nih.gov/pubmed/19608479
VL - 3
ER -